Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists investigate the mystery of weight regain

NCT ID NCT05748158

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at why people with obesity often regain weight after losing it through a behavioral weight loss program. About 205 adults aged 25-59 will first lose at least 7% of their body weight, then be followed for a year to track how much weight they regain. The goal is to understand the body's physiological changes that make weight maintenance difficult.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why some people regain weight after dieting, pointing toward better strategies to maintain weight loss.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any direct intervention, and results may not apply to everyone with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 205 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 25 - \<60 years 2. BMI: 30 - \<40 kg/m2 at the first screening visit 3. Within 5% of current weight, for the past 6 months at the first screening visit 4. Able to participate in ergometry testing 5. Has a smart phone, tablet or computer with access to the internet Exclusion Criteria: 1. If 25-29 years old, \> 5% deviation from maximum weight (excluding weights while pregnant) since age 25 years 2. If at least 30 years old, \> 5% deviation from maximum weight (excluding weights while pregnant) in last 5 years or ≥ 10% deviation from maximum weight (excluding weights while pregnant) since age 30 years 3. History of pulmonary embolus in the past 6 months 4. Cardiovascular disease (e.g. myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack) within the past 6 months 5. Current major depressive disorder or history of major depressive disorder within 2 years 6. Any regular tobacco or nicotine use in the past year 7. Currently engaging in intense physical training or training for a sports event including, but not limited to, a marathon or body building 8. Currently pregnant, or less than one-year post-partum or actively planning to become pregnant within the next two years 9. Presently classified as being in New York Heart Association Class II or greater or dysrhythmia 10. Diabetes (type 1 or 2 - HbA1c ≥ 6.5%, fasting glucose ≥ 126 mg/dL) or currently taking a glucose lowering medication 11. Thyroid disease requiring hormones or medication or TSH \< 0.5 or \> 5 mIU/L 12. Renal disease requiring dialysis 13. Known HIV infection 14. ALT or AST greater than 5 times the upper limit of normal or active gall bladder disease 15. Significant anemia (Hgb \< 10 g/dL) or thrombocytopenia (platelet count \< 60,000 /mm3) 16. Leukopenia defined as: Males: WBC \< 3,100 /mm3 or (WBC 3,100 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result) Females: WBC \< 3,400 /mm3 or (WBC 3,400 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result) 17. Active cancer or current chemotherapy treatment, or history of cancer requiring treatment in the past 5 years except for non-melanoma skin cancers or cancers that have clearly been cured 18. Current or past history of anorexia nervosa or bulimia nervosa 19. Current or past diagnosis of binge eating disorder 20. Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder) 21. Unwillingness to abstain from marijuana/cannabis use for 3 weeks at each of the four assessment time points 22. Known or suspected abuse or misuse of alcohol, prescription drugs, or recreational drugs 23. Antiretroviral therapy (ART), including treatment for HIV, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) within the past 3 months 24. Regularly taking medication or supplement known to affect appetite, energy expenditure, or weight (e.g. appetite suppressants, steroids-including inhaled steroids but not topical, alpha-blockers, beta-blockers, certain psychotropic medications) 25. Currently taking anticoagulant medication 26. Currently enrolled in a supervised weight reduction program 27. Prior or planned bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty 28. Severely restricted diets: Vegan (no meat, fish, dairy, eggs, or honey), very low carbohydrate (\<15% calorie as carbohydrate), very low fat (\<15% calories as fat), or strictly gluten free 29. Current celiac or diagnosed gluten intolerance or inflammatory bowel disease requiring specialized diet 30. Night or rotating shift worker 31. Known severe allergy (e.g. anaphylaxis) to nuts or other foods 32. Systolic blood pressure (BP) \<90 mmHg and/or diastolic BP \<60 mmHg on 2 measurements during the clinical screening visit. 33. Systolic blood pressure (BP) \>160 mmHg and/or diastolic BP \>100 mmHg on at least 2 measurements during the clinical screening visit or resting heart rate \< 45 beats per minute or \>100 on 2 measurements during the clinical screening visit. 34. Metal implants, piercings that cannot be removed, or metal-based tattoos or hair treatments 35. Exceeds limitations to fit dual-energy X-ray absorptiometry (DXA) field of view 36. Known allergy to lidocaine or acetaminophen 37. Non-compliance with appointments or tasks (food diaries, etc.) during the screening phase 38. Blood clotting disorder or INR \> ULN or PT \> ULN or (a)PTT \> ULN 39. Tendency to form thick or raised scars 40. Inability to achieve weight stability (defined in section 4.2.1) during the 2 weeks prior to initiation of the baseline Doubly Labeled Water (DLW) assessment 41. At high risk for suicide, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Body-Weight Trajectory Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

  • Drexel University

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.